We recently compiled a list of the 14 Worst 52-Week High Stocks to Buy According to Short Sellers. In this article, we are ...

TG Therapeutics stock popped Wednesday after the company unveiled promising five-year test results for its multiple sclerosis ...

During the last three months, 4 analysts shared their evaluations of TG Therapeutics TGTX, revealing diverse outlooks from ...

TG Therapeutics (TGTX) presented updated data from the ENHANCE Phase 3b trial evaluating BRIUMVI in patients with relapsing forms of ...

TG Therapeutics announced it updated its data presentations to include details from the ULTIMATE I & II Phase 3 trials, evaluating BRIUMVI. The data showed that continued use of BRIUMVI resulted ...

Most readers would already be aware that TG Therapeutics' (NASDAQ:TGTX) stock increased significantly by 49% over ...

TG Therapeutics' Briumvi shows strong revenue growth, with Q2 2024 revenue up 350% YoY, leading to an upgraded full-year guidance of $290-$300 million. Expansion into CAR-T therapy for autoimmune ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on TG Therapeutics (TGTX – Research Report) and Boston Scientific (BSX – Research Report) with bullish ...

The market has climbed 2.6% in the last 7 days and is up 31% over the last 12 months, with earnings forecast to grow by 15% ...

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: TGTX), today announced the schedule of upcoming data presentations, highlighting data from both the ULTIMATE I & II ...

During the last three months, 4 analysts shared their evaluations of TG Therapeutics (NASDAQ:TGTX), revealing diverse outlooks from bullish to bearish. The table below summarizes their recent ...

(RTTNews) - TG Therapeutics (TGTX) presented updated data from the ENHANCE Phase 3b trial evaluating BRIUMVI in patients with relapsing forms of multiple sclerosis. The company said the data ...